Skip to content

Intestinal Juice Transplantation Combined with Fecal Microbiota Transplantation for Children with ASD: a Single-Center, Placebo-Controlled Study

Intestinal Juice Transplantation Combined with Fecal Microbiota Transplantation for Children with ASD: a Single-Center, Placebo-Controlled Study

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100043929
Enrollment
Unknown
Registered
2021-03-05
Start date
2021-03-01
Completion date
Unknown
Last updated
2021-07-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Autism spectrum disorder

Interventions

Intervention group:IJT capsules and FMT capsules
Control group:FMT capsules

Sponsors

Department of Colorectal Disease, the Tenth People's Hospital, Tongji University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
3 Years to 13 Years

Inclusion criteria

Inclusion criteria: (1) Age 3-13 years old, male or female; (2) Meeting the ASD diagnostic criteria of the Diagnostic and Statistical Manual of Mental Disorders-5 (DSM-5) of the American Psychiatric Association; (3) Accompanied with diarrhea, constipation, abdominal distension and/or food allergy/intolerance for at least 6 months and above symptoms occurred in the last 3 months; (4) The subject's guardian should be matched with the donor screening criteria of Expert consensus on the establishment of standardized methodology and clinical application for FMT, and sign the informed consent, agreeing to perform the nasojejunal tube implantation and collect intestinal juice. The intestinal juice will be made into IJT capsules, which will be used for his/her child. The child and guardian should also be cooperated with the whole process of the clinical trial and be collected clinical data, blood, saliva, urine and feces samples; (5) Able to swallow 3# FMT capsules by themselves.

Exclusion criteria

Exclusion criteria: (1) Diagnosis of Rett syndrome. (2) Previous history of brain injury, cerebral palsy, encephalitis or other brain organic diseases; (3) Diagnosis of other mental diseases; (4) Diagnosis of intestinal organic diseases, such as congenital megacolon, intestinal obstruction, intussusception, inflammatory bowel disease and etc. (5) There are pathological intestinal inflammatory changes, such as inflammatory bowel disease; (6) Using probiotics, antibiotics and other drugs affecting intestinal flora in a planned way within the last 3 months or in the following 6 months; (7) The guardian does not consent to nor is unable to perform the nasojejunal tube implantation, nor the guardian does not meet the donor screening criteria.

Design outcomes

Primary

MeasureTime frame
Diversity and richness of flora;

Secondary

MeasureTime frame
Childhood Autism Rating Scale;Autism Behavior Checklist;Bristol Stool Form Scale;Gastrointestinal Symptom Rating Scale;Metabolic profile;

Countries

China

Contacts

Public ContactQin Huanlong

Department of Colorectal Disease, Shanghai Tenth People's Hospital

qin_huanlong@126.com+86 15896453859

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 11, 2026